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Abstract: PET using fluorine-18 fluorocholine (18F-fluorocholine) may detect malignancies that involve altered choline 
metabolism. While 18F-fluorocholine PET/CT has shown greater sensitivity for detecting hepatocellular carcinoma 
(HCC) than 18F-fluoro-D-deoxyglucose (FDG) PET/CT, it is not known whether it can also detect intrahepatic 
cholangiocarcinoma (ICC), a less common form of primary liver cancer. Clinical, radiographic, and histopathologic 
data from 5 patients with ICC and 23 patients with HCC from a diagnostic trial of liver 18F-fluorocholine PET/CT 
imaging were analyzed to preliminarily evaluate 18F-fluorocholine PET/CT for ICC. Imaging was correlated with whole-
genome expression profiling to identify molecular pathways associated with tumor phenotypes. On PET/CT, all ICC 
tumors demonstrated low 18F-fluorocholine uptake with a significantly lower tumor to mean background uptake ratio 
than HCC tumors (0.69 vs. 1.64, p < 0.0001), but no corresponding significant difference in liver parenchyma uptake 
of 18F-fluorocholine between ICC and HCC patients (8.0 vs. 7.7, p = 0.74). Two ICC patients demonstrated increased 
tumor metabolism on FDG PET/CT, while immunohistochemical analysis of ICC tumors revealed overexpression of 
glucose transporter 1 (GLUT-1) and hexokinase indicating a hyper-glycolytic phenotype. Gene expression analysis 
revealed down-regulation of farnesoid-X-receptor and other lipid pathways in ICC relative to HCC, and up-regulation 
of glycolytic pathways and GLUT-1 by HIF1α. These results imply limited utility of 18F-fluorocholine in ICC, however, 
significant metabolic differences between ICC, HCC, and parenchymal liver tissue may still provide clues about 
the underlying liver pathology. Gene and protein expression analysis support hyperglycolysis as a more dominant 
metabolic trait of ICC.
Keywords: Cholangiocarcinoma, hepatocellular carcinoma, positron emission tomography, fluorocholine
Background
Cholangiocarcinoma is a malignancy that origi-
nates from biliary epithelia and arises either as 
an extra-hepatic lesion in the biliary tree, or 
less commonly, as a mass lesion within the 
liver parenchyma itself. The latter, termed intra-
hepatic cholangiocarcinoma (ICC), historically 
has accounted for only 10% of all primary liver 
cancers, however its incidence appears to be 
increasing in some regions [1]. It is difficult to 
explain the increasing incidence based on 
established risk factors for cholangiocarcino-
ma. Risk factors for cholangiocarcinoma typi-
cally associate with chronic biliary inflamma-
tion, and include primary sclerosing cholangi-
tis, liver parasitic infection, and congenital 
abnormalities of the biliary tract. More recent 
studies have identified viral hepatitis, cirrhosis, 
diabetes, obesity, and alcohol consumption as 
potential additional ICC risk factors [2]. These 
are also risk factors for hepatocellular carcino-
ma (HCC), the most common primary liver can-
cer and one that is also rising in incidence. Due 
to the increasing incidence of HCC and ICC, it is 
becoming more important to confidently dis-
criminate between these liver tumors, particu-
larly since ICC is refractory to several treat-
ments for HCC [3-5]. 
Extra-hepatic cholangiocarcinoma, which is 
more common than ICC, frequently presents 
18F-fluorocholine PET/CT in intrahepatic cholangiocarcinoma
74 Am J Nucl Med Mol Imaging 2016;6(1):73-83
with signs of biliary obstruction before forming 
a significant mass. Thus it is rarely confused 
with HCC. In contrast, ICC is mass-forming and 
there is a growing appreciation that its radio-
graphic appearance can vary substantially and 
overlap with HCC [3]. Histology obtained from 
percutaneous biopsies also may not consis-
tently differentiate ICC from HCC variants and 
metastatic adenocarcinoma, and while clinical 
risk factors, cirrhosis severity, and serum tumor 
markers such as cancer antigen 19-9 (CA 19-9) 
may be helpful, the diagnosis of liver tumors 
may ultimately rely on tissue examination after 
hepatic resection [2, 3].
An investigational positron emission tomogra-
phy (PET) technique for imaging choline metab-
olism using the radiopharmaceutical tracer flu-
orine-18 fluorocholine (18F-fluorocholine) has 
recently shown clinical utility for detecting HCC 
[6]. However, there is little data on imaging 
other liver tumors with 18F-fluorocholine. There 
is also limited data on the molecular changes 
that may lead to specific radiographic and 
molecular imaging phenotypes in liver cancer. 
This pilot study is the first to report findings on 
18F-fluorocholine PET/CT in ICC, and does so in 
conjunction with gene and protein expression 
analysis in an attempt to further inform the 
development of molecular imaging strategies 
for liver tumors.
Methods
Patients
Among patients taking part in a U.S. registered 
clinical trial of liver PET/CT imaging using 
18F-fluorocholine PET/CT (NIH NCT01395030), 
5 patients were identified as diagnosed with 
ICC based on post-surgical histopathology. In 
addition to reviewing tumor radiologic and his-
topathologic features from these 5 patients, a 
transcriptomic analysis was conducted to com-
pare whole-genome gene expression profiles 
available from 3 of the ICC tumors and 23 HCC 
tumors collected consecutively from other 
patients participating in the trial.
Written informed consent was obtained from all 
patients in accordance with an institutional 
review board approved clinical research proto-
col that adheres to the ethical guidelines of the 
Declaration of Helsinki and its subsequent 
amendments. All patients were recruited to the 
study by hepatobiliary/transplant surgeons 
affiliated with a single-institution multi-disci-
plinary liver disease management program. 
Clinical records were used to collect data on 
patient demographics and liver disease risk 
factors such as infection by viral hepatitis and 
significant alcohol use (defined as at least 2 
alcoholic beverages daily for 10 years). The 
study also collected clinical laboratory data, 
including bilirubin, alkaline phosphatase, albu-
min, and tumor markers including CA 19-9 and 
alpha-fetoprotein levels. 
Tumor and non-tumor liver tissue samples were 
collected for research at the time of hepatic 
resection if agreed upon by the attending sur-
geon. Collected samples were divided using 
sterile instruments and placed into formalin, 
liquid nitrogen, and RNA-preservative (RNALa- 
ter, Thermo Fisher Scientific, Waltham, Massa- 
chusetts). These samples were stored under 
appropriate conditions until further analysis.
Fluorine-18 fluorocholine synthesis 
Fluorine-18 fluorocholine synthesis was per-
formed by fluorination of ditosylmethane with 
fluorine-18 followed by alkylation of the fluoro-
tosylmethane intermediate with dimethyletha-
nolamine using a chemical process control unit 
(CTI/Siemens CPCU, CTI/Siemens, Knoxville, 
TN) [7]. All synthesis products passed standard 
assays for radiochemical purity, radionuclide 
identity, chemical purity, and non-pyrogenicity 
prior to injection. Radiochemical purity was 
greater than 99%. 
PET/CT imaging
PET/CT imaging was performed with a Philips 
Gemini TF-64 PET/CT scanner (Philips Health- 
care, Andover, Massachusetts) using 18F-fluo- 
rocholine under an investigational new drug 
protocol. A CT scan without intravenous con-
trast was first performed in the supine position. 
The 64-channel helical CT scanning parame-
ters were: 120 kV, 50 mA/slice, rotation time 
0.75 seconds, slice thickness/interval 5.0 mm. 
Following injection of 2.2 to 3.0 MBq/kg of the 
tracer through a peripheral intravenous line, 
dynamic emission scanning was conducted for 
the first 40 minutes of radiopharmaceutical 
distribution, after which static PET scans of the 
liver were obtained. PET image reconstruction 
was performed using a maximum likelihood 
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expectation maximization algorithm using CT 
data for attenuation correction. 
PET/CT images were reviewed on a multi-
modality imaging workstation (Hybrid PDR, ver-
sion 1.4c; Hermes Medical Solutions). Liver 
lesions were identified on PET/CT in correlation 
with available clinical radiographic examina-
tions and a volume region of interest (ROI) was 
placed around the tumor region. The standard-
ized uptake value (SUV), defined as the mea-
sured radioactivity of a pixel divided by the 
injected radioactivity normalized to body 
weight, was used as the measure of tissue 
uptake on static PET images and the maximum 
SUV (SUVmax) of each ROI was determined. A 
tumor to mean background ratio (TBR) was cal-
culated for all liver tumors by dividing the tumor 
SUVmax by the average SUV corresponding to a 
2 cm diameter ROI placed in the liver parenchy-
ma adjacent to the tumor ROI. 
Gene expression array analysis
In 3 cases of moderately-differentiated ICC, 
there was tissue sample material of sufficient 
pression BeadChips (Illumina Inc., Sunnyvale, 
California). Arrays were scanned using the 
iScanTM instrument and expression levels were 
quantified using GenomeStudio software (Illu- 
mina Inc., Sunnyvale, CA).
Gene expression array data consisted of the 
expression levels of 20792 genes for 26 
patients. The array data was pre-processed by 
generalized log2 transformation with back-
ground subtraction, quantile normalization, 
and row centering [8]. Sparse rank-1 matrix fac-
torizations were used to identify a small num-
ber of genes that characterized global differ-
ences in gene expression between the ICC and 
HCC samples with false discovery rate (FDR) 
estimated by permutation testing. 
An analysis for activated gene pathways, 
upstream regulators, downstream targets, and 
biological effects was performed using Inge- 
nuity Pathway Analysis software (IPA, QIAGEN 
Redwood City, California). This software served 
to identify molecular mechanisms that may be 
responsible for the observed differences in 
gene expression between the ICC and HCC 
Table 1. Patient demographic, imaging, and immunohistochemical 
findings
ID Age Gender Size (cm) SUV Ratio GLUT-1 HK CKA HIF1
tu nl tu nl tu nl tu nl
1 52 F 5.5 0.65 2 1 2 2p 2 2 2 1
2 63 M 4.2 0.66 2 0 2 1 2 2 1 0
3 65 M 3.5 0.87 2c 0 0 2 2 1 2c 0
4 54 M 7.4 0.75 2 0 2 2p 2 2 2 2p
5 56 M 6.5 0.51 2 1 2 1p 2 1 2 1p
IHC stain intensity was rated as: 0 = absent or weak, 1 = modest, 2 = moderate, 
and 3 = intense. GLUT-1 intensity was rated for the cell membrane and HIF-1 
expression was rated for the nucleus. Abbreviations are as follows: SUV = standard-
ized uptake ratio, GLUT-1 = glucose transporter-1, HK = hexokinase, CKA = choline 
kinase alpha, HIF1 = hypoxia inducible factor 1, tu = tumor tissue, nl = native liver 
tissue, p = patchy cellular distribution, c = cytoplasmic localization only.
Table 2. Laboratory values of patients diagnosed with ICC
Patient Bili-rubin Alk Phos AFP Ca 19-9 HBsAg HBcAg HCV
1 0.4 80 3 1 No No No
2 9.6 167 12 2,871 No No No
3 0.5 84 2.9 34 Yes No No
4 0.4 186 133 376 No No No
5 0.2 128 2.6 108 No No No
AFP = alpha fetoprotein, CEA = carcinoembryonic antigen, CA 19-9 = cancer antigen 
19-9, HBsAg = hepatitis B surface Antigen, HBcore = hepatitis B core antigen, HCV 
= hepatitis C virus.
quality for transcriptional 
analysis. Gene expression 
profiles from these samples 
were compared to the tumor 
expression profiles from 23 
consecutive HCC patients 
that had also underwent 
18F-fluorocholine PET/CT be- 
fore surgery. First, RNA was 
extracted from homogenized 
frozen tissue lysates in RLT 
Plus buffer with the AllPrep 
DNA/RNA Mini kit (Qiagen, 
Valencia, CA) following manu-
facturer’s protocol. The iso-
lated RNA was stored at 
-80°C until used. The quality 
of the total RNAs was checked 
on a Bioanalyzer using RNA 
6000 Nano chips (Agilent, 
Santa Clara, CA). The isolated 
RNA was processed following 
the Illumina whole-genome 
cDNA-mediated annealing, 
selection, extension, and liga-
tion protocol with resulting 
polymerase chain reaction 
products hybridized onto the 
Illumina HumanHT-12 v4 Ex- 
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samples. Candidate upstream regulators of a 
given signature were ranked by the degree to 
which the change in expression of their down-
stream targets was consistent with the current 
biomedical literature (Score) and the likelihood 
that the observed intersection of target genes 
with the signature was a chance event (P-value). 
Upstream regulators with scores greater than 
2.0 and P-values less than 0.01 were consid-
ered significant. The downstream targets of 
top-ranked upstream regulators were then fur-
ther analyzed in IPA to identify genes and path-
ways associated with specific disease func-
tions and biological processes such as cellular 
growth and proliferation, inflammatory res- 
ponse, angiogenesis, and lipid metabolism.
Validation by immunohistochemistry
Tumor and liver tissue were taken from the sur-
gical resection specimen, fixed with 10% for-
malin, and embedded in a paraffin block. 
Immunohistochemical (IHC) analysis of de-par-
affinized rehydrated tumor and parenchymal 
tissues was performed using an automated 
antibody staining platform (Dako, Inc., Car- 
pinteria, CA, USA). Choline kinase alpha (CKA) 
was evaluated using a commercial antibody 
(choline kinase alpha rabbit polyclonal anti-
body, Sigma-Aldrich Co. LLC., St. Louis, Mi- 
ssouri) in accordance with the manufacturer’s 
protocol and an antibody dilution to 1:30. 
Hexokinase-2 (HK2) was evaluated using a 
commercial antibody (hexokinase II rabbit 
monoclonal antibody, Cell Signaling Technology, 
Inc., Danvers, Massachusetts) with antibody 
dilution adjusted to 1:100. Glucose transport-
er-1 (GLUT-1) expression was evaluated using a 
commercial antibody (Glucose Transporter 1 
rabbit monoclonal, Cell Marque, Rocklin, 
California) with antibody dilution adjusted to 
1:100. Hypoxia inducible factor 1 alpha (HIF1A) 
expression was evaluated using a commercial 
antibody (Hα111a mouse monoclonal, Enzo, 
Life Sciences, Inc., Farmingdale, New York) with 
antibody dilution adjusted to 1:100. Antibody 
detection was conducted using a horseradish 
peroxidase HiDef polymer detection system 
with diaminobenzidine as substrate (Cell Mar- 
que, Rocklin, California). A hepatobiliary pathol-
Figure 1. Intrahepatic cholangiocarcinoma demonstrating low 18F-fluorocholine uptake and uniformly high 18F-FDG 
uptake. Image intensity scale is in SUV units. A liver mass was incidentally detected on 18F-FDG PET/CT in Patient 1 
during clinical radiographic follow-up of breast cancer. FDG PET (A) and PET/CT (C) images demonstrate increased 
FDG uptake corresponding to a 4.0 cm mass in the right hepatic lobe (arrow). In contrast, PET (B) and correspond-
ing PET/CT (D) images obtained following administration of 18F-fluorocholine show diminished radiopharmaceutical 
uptake by the tumor. Surgical pathology confirmed the diagnosis of moderately differentiated ICC. 
18F-fluorocholine PET/CT in intrahepatic cholangiocarcinoma
77 Am J Nucl Med Mol Imaging 2016;6(1):73-83
ogist (OC) visually evaluated each section at 
200X and 400X, grading each tumor and liver 
tissue specimen based on a standardized scor-
ing system adapted for evaluating liver tumors, 
with marker intensity rated on an ordinal scale 
from 0 (no staining) to 3 (intense staining), cell 
distribution classified as patchy or diffuse, and 
the predominant cellular localization (nucleus, 
cytoplasm, or membrane) identified for each 
antibody [9, 10]. 
Statistical analysis
Descriptive and general statistical calculations 
were performed using JMP 11 Pro (SAS 
Institute, Inc., Cary, NC). Categorical compari-
sons (i.e. ICC patients vs. HCC patients) were 
conducted by t-test. All tests were two-tailed 
and a p-value < 0.05 was considered statisti-
cally significant unless otherwise stated.
Results
Each patient underwent a partial hepatectomy 
with histopathologic examination of the primary 
tumor confirming the final cancer diagnosis. 
Tumor diameter ranged from 1.2 cm to 6.5 cm 
measured in the longest axis on gross patholo-
gy examination prior to formalin fixation. ICC 
tumors were classified by histology as moder-
ately differentiated in 4/5 patients and well dif-
ferentiated in one patient (Patient 3).
Patient clinical parameters are summarized in 
Table 1. None of the 5 patients with ICC had a 
clinical history of underlying cirrhosis or classi-
cal risk factors for ICC, although one patient 
had chronic HBV infection. Laboratory values 
and hepatitis serology are summarized in Table 
2. 
PET imaging findings
Tumor 18F-fluorocholine uptake was not signifi-
cantly increased with respect to background 
liver uptake in all 5 ICC cases (examples shown 
in Figures 1 and 2). The SUVmax of ICC tumors 
ranged from 4.1 to 7.6, while TBR ranged from 
0.51 to 0.87. The SUVmax of ICC tumors was 
significantly lower than that of the 23 HCC 
tumors that had undergone gene expression 
profiling (mean SUVmax 5.5 vs. 12.2, p < 
0.0001). TBR differed significantly between the 
Figure 2. Intrahepatic cholangiocarcinoma demonstrating heterogeneously increased 18F-FDG uptake but low 18F-
fluorocholine uptake. Image intensity scale is in SUV units. Patient 4 presented with a liver mass detected on 
ultrasound. FDG PET (A) and PET/CT (C) images demonstrate an area of heterogeneously increased FDG uptake 
corresponding to a 7.4 cm mass in the left hepatic lobe (arrow). Corresponding 18F-fluorocholine PET (B) and PET/CT 
(D) images show diminished 18F-fluorocholine uptake in this region. The diagnosis of moderately differentiated ICC 
was established by surgical pathology examination of the tumor. 
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ICC and HCC tumors (0.69 vs. 1.64, p < 0.0001), 
but there was no significant difference in mean 
liver SUV between the 5 ICC and 23 HCC 
patients (8.0 vs. 7.7, p = 0.74). 
In two patients with ICC that also underwent 
clinical imaging with 18F-FDG PET/CT, tumors 
demonstrated increased FDG uptake with a 
SUVmax of 10.6 in Patient 1 and a SUVmax of 
9.6 in Patient 4. In Patient 1, the area of 
increased tumor FDG uptake correlated pre-
cisely with an area of diminished liver uptake 
on 18F-fluorocholine PET (Figure 1). In Patient 4, 
the area of increased tumor FDG uptake corre-
sponded on 18F-fluorocholine PET/CT to iso-
intense uptake along the tumor periphery and 
diminished uptake in the central part of the 
tumor (Figure 2). Small zones of focal necrosis 
were identified in the tumor specimen of Patient 
4, although the extent of necrosis did not cor-
respond to the spatial extent of diminished 
18F-fluorocholine uptake on PET/CT.
Expression array analysis 
Differential expression analysis of the tran-
scriptional array data resulted in a 849-gene 
signature that discriminated between the ICC 
natures defined by each of these regulators, 
consisting of genes that were either directly or 
indirectly targeted by the regulator, were also 
submitted for pathway analysis, revealing the 
following states for all 12 regulators: 1) signifi-
cant inhibition of FXR signaling and lipid metab-
olism, and 2) a predicted increase in glucose 
consumption due to over-expression of GLUT-1 
and GLUT-3 via HIF1A signaling (Table 4). 
Immunohistochemical analysis of protein ex-
pression
IHC analysis of glucose transporter and hexoki-
nase expression was performed as a surrogate 
indicator of tumor glycolytic status to validate 
the findings from gene expression analysis. 
Tumors from all 5 patients with ICC demon-
strated increased GLUT-1 expression relative to 
peritumoral liver tissue. However, GLUT-1 local-
ization was predominantly cytoplasmic in the 
case of well-differentiated ICC while it more 
specifically localized to the cell membrane in 
the moderately-differentiated tumors. IHC 
expression of HK2 was also more intense or 
diffuse in the 4 moderately-differentiated 
tumors but decreased in the well-differentiated 
tumor. With regards to choline metabolism, 
Figure 3. Row-clustered heat map of the 849-gene ICC signature. The first 
3 columns represent ICC samples and the next 23 columns represent HCC 
samples. The color-coded entries represent the normalized expression of 
a given gene in a given sample. The heat map captures the heterogeneity 
that is inherent in the tumor samples while at the same time characterizing 
the transcriptional differences between the ICC and HCC tumors with high 
confidence (FDR = 2.5%). Note that the clustered heat map sharply discrimi-
nates the ICC samples from the HCC samples although some resemblance 
to ICC can be appreciated for the HCC sample that clustered closest to the 
ICC samples (sample 4). 
and HCC tumor samples with 
an empirical FDR of 2.5%. This 
is illustrated by a heat map in 
Figure 3 where columns 1 to 3 
represent 3 ICC samples and 
columns 4 to 26 represent 23 
HCC samples. IPA analysis 
of the ICC signature reveal- 
ed Farnesoid-X-receptor (FXR) 
activation as the most signifi-
cant IPA canonical pathway (P 
= 1.7-e-43, 55/127 genes), 
with 53 of 55 ICC signature 
genes being down-regulated. 
Inhibition of lipid metabolism 
was a highly significant down-
stream effect predicted by the 
signature, involving numerous 
lipid related functions as sum-
marized in Table 3. IPA analy-
sis also identified a set of 12 
significant upstream regula-
tors of the 849-gene signa-
ture that included notable 
cancer-related genes such as 
TNF, IL1B, TGFB1, and Her2/
Neu (Table 4). Individual sig-
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there was comparable expression of CKA 
between tumor cells and hepatocytes in 3 
tumors and a heterogeneous but sparse pat-
tern of marginally increased expression in one 
well-differentiated tumor and one moderately-
differentiated tumor. Increased localization of 
HIF1α in the tumor cell nuclei was observed in 
all 4 moderately-differentiated tumors, while 
only increased cytoplasmic localization was 
noted in the well-differentiated tumor. Repre- 
sentative IHC images from Patient 5 are shown 
in Figure 4. Individual IHC results are summa-
rized in Table 1.
Discussion
Many types of cancer harbor evidence of inc- 
reased choline metabolism, including cancers 
of the breast, colon, prostate, lung, brain, and 
liver [11-15]. In a single-institution clinical trial, 
PET imaging using 18F-fluorocholine, a positron-
emitting synthetic substrate of CKA, was asso-
ciated with a higher detection rate for HCC than 
conventional PET with FDG [6]. The results of 
the present pilot study, while derived from a 
limited number of patients, strongly suggest 
that ICC may be elusive to detection on the 
basis of 18F-fluorocholine uptake, and despite 
being another primary liver malignancy, may 
inhibit lipid pathways through direct and indi-
rect effects on their downstream targets. 
Notably, 12 significant upstream regulators of a 
gene signature that differentiated ICC from 
HCC were predicted to inhibit farnesoid 
X-receptor (FXR) activation. FXR is a nuclear 
receptor known to be involved in the regulation 
of hepatic glucose, lipid, and bile acid metabo-
lism that has also recently been implicated in 
the development of HCC [16, 17]. 
While differential expression analysis involving 
tumors is usually conducted as a comparison 
between malignant and corresponding normal 
tissue, the approach taken in the present study 
was to compare gene expression between ICC 
and HCC. We reasoned that since HCC tumors 
typically demonstrate increased 18F-fluorocho- 
line uptake relative to liver tissue(6), the differ-
ential signature between ICC and HCC would be 
better for identifying genes associated with 
tumor metabolic PET phenotype. Differential 
expression analysis between ICC and HCC may 
also serve to “filter out” mutually-expressed 
cancer-related genes, and aid in identifying the 
most significant molecular pathways for distin-
guishing these two types of primary liver can- 
cer.
Table 3. The most significant downstream effects of the 
ICC signature on lipid metabolism
Lipid Function P-Value Activation Score # Genes
Metabolism of terpenoid 6.57E-35 -2.720 76
Fatty acid metabolism 8.63E-34 -3.342 107
Oxidation of lipid 1.16E-21 -2.747 49
Transport of lipid 1.50E-17 -3.680 40
Metabolism of retinoid 1.85E-16 -2.401 22
Hydroxylation of lipid 5.10E-16 -2.744 16
Flux of lipid 5.57E-16 -3.935 31
Conjugation of lipid 9.42E-16 -3.065 13
Metabolism of tretinoin 8.69E-15 -2.083 16
Excretion of lipid 5.26E-14 -2.559 16
Efflux of lipid 5.27E-14 -3.595 28
Oxidation of fatty acid 7.93E-14 -2.043 34
Transport of steroid 1.45E-13 -3.291 22
Glucuronidation of lipid 4.89E-13 -3.058 10
Efflux of cholesterol 5.13E-12 -3.227 24
Efflux of phospholipid 4.42e-06 -1.988 8
Lipid functions are ordered by the intersection p-values of the genes as-
sociated with a given lipid function by IPA. Note that negative activation 
scores indicate inhibition of lipid function.
differ substantially from HCC with 
regards to the consumption of meta-
bolic substrates. While it is disappoint-
ing that 18F-fluorocholine PET/CT alone 
may not be useful for primary detec-
tion of ICC, the metabolic differences 
between ICC and HCC, as preliminarily 
identified in this study, may be helpful 
in further developing molecular imag-
ing strategies for differentiating liver 
tumors.
We are not aware of any previous study 
of ICC using 18F-fluorocholine PET/CT. 
Currently, 18F-fluorocholine is not clini-
cally available in many countries. The 
ICC tumors in this study consistently 
exhibited poor avidity for 18F-fluoro- 
choline in the absence of significant 
tumor necrosis that could have other-
wise explained low accumulation of 
the tracer. Furthermore, differential 
expression analysis between ICC and 
HCC tumors linked ICC with the activa-
tion of regulatory molecules that may 
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While our results are limited by the number of 
patients being studied, transcriptomic and IHC 
analyses were in agreement in suggesting glu-
cose metabolism to be more promising than 
choline metabolism as the basis for detecting 
ICC. Therefore, these molecular profiling results 
corroborate with the negative findings of this 
pilot imaging study. While 18F-fluorocholine 
PET/CT may have limited utility for the primary 
detection of ICC, clinical PET studies have pre-
viously shown FDG PET/CT to have a reason-
ably high detection rate for ICC in the range of 
70 to 90% [18, 19]. This is in contrast to HCC, 
for which FDG PET has been shown to have low 
sensitivity for detecting the primary tumor (6, 
20). A potential molecular basis for ICC detec-
tion with FDG PET may be an increase in tumor 
GLUT1 and HK2 expression, and indeed, the 
expression of these proteins has been corre-
lated with increased tumor FDG uptake on PET 
imaging in moderately- and poorly-differentiat-
ed cholangiocarcinoma [21, 22]. In contrast, 
GLUT1 expression has not been found to cor-
relate strongly with tumor FDG uptake in HCC 
[23]. Notably, well-differentiated ICC may exhib-
it a weaker glycolytic phenotype [21]. This pat-
tern was also noticed in the present study with 
the lower expression of glycolysis-related mark-
ers by a well-differentiated tumor. 
Discordant tumor avidity for 18F-fluorocholine 
and FDG may signify coincident changes in the 
pathways regulating phospholipid and glucose 
metabolism in ICC. In the present study, the 
molecular basis of these dual metabolic altera-
tions was investigated by gene expression pro-
filing and IHC analysis. While less is known 
about choline metabolism in ICC, hyperglycoly-
sis and overexpression of GLUT-1 has been 
associated with tumor biologic aggressiveness 
and poor clinical outcome in ICC [21]. In the 
present study, increases in glucose transporter 
expression in ICC were associated with HIF1A 
signaling, and, multiple cancer-related genes 
were identified by pathway analysis as poten-
tially driving this process. Conversely, the sup-
pression of lipid metabolism pathways and FXR 
signaling, as predicted by this same gene sig-
nature, also helped to explain the low tumor 
avidity for 18F-fluorocholine seen in ICC. 
This single-institution clinical pilot study of ICC 
has inherent limitations typical of small cohort 
studies. Furthermore, patients were recruited 
through a single referral center, and not all 
patients received a correlative clinical FDG PET 
scan or contributed sufficient tissue for gene 
expression analysis. Each of these factors raise 
the potential for bias. Furthermore, IHC valida-
tion of protein expression and metabolic PET 
phenotype was performed using a limited 
selection of research antibodies that may not 
be sufficient in characterizing the overall state 
of cellular metabolic proteins. For example, 
while 18F-fluorocholine is a synthetic substrate 
of CKA, tumor CKA expression may not neces-
Table 4. Top upstream regulators of the ICC signature and their downstream effects 
Upstream 
Regulator IPA Score
Intersection
P-Value
Number of Genes 
in Signature
P-Value for GLUT1/3
Activation via HIF1A
P-Value for Inhibition of FXR 
Activation & Lipid Metabolism
TNF 3.829 4.82e-29 345 6.64e-07 2.11e-35
IL1B 4.513 1.66e-21 293 1.83e-06 1.60e-38
TGFB1 5.545 8.68e-21 345 6.64e-07 5.42e-34
IL6 2.683 2.55e-20 360 1.06e-05 4.34e-44
IL1 2.347 1.24e-16 267 5.00e-07 5.00e-35
Her2/neu 2.917 8.67e-16 270 5.49e-07 4.41e-21
NR0B2 3.175 2.26e-14 393 9.92e-05 4.21e-49
EGFR 3.888 9.45e-13 288 8.42e-06 4.35e-31
HIF1A 3.141 4.04e-11 273 1.42e-06 2.00e-25
ERK1/2 3.195 1.52e-07 286 9.42e-07 2.48e-24
P38/MAPK 3.063 7.59e-07 302 1.24e-05 4.03e-36
VEGF 2.710 1.79e-06 228 1.22e-06 1.67e-21
A signature for a given regulator is composed of its direct and indirect downstream targets in the ICC signature. The upstream 
regulators are ordered by intersection P-Value. For each regulator shown, IPA score, intersection P-Value, signature size, and p-
values for GLUT1/3 activation in ICC via HIF1A signaling and inhibition of FXR Activation and lipid metabolism are given. Scores 
greater than 2.0 and intersection P-values less than 1.0e-05 are considered significant.
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sarily reflect tumor avidity for 18F-fluorocholine 
on PET imaging since intracellular accumula-
tion of 18F-fluorocholine is dependent on both 
its membrane transport and intracellular phos-
phorylation [13]. This could explain why IHC 
analysis in this study did not reveal decreased 
protein expression of CKA in all ICC tumors as 
would otherwise be predicted by the low TBR 
on 18F-fluorocholine PET/CT. Tumor 18F-fluoro- 
choline uptake may have correlated more 
cers that would otherwise not be identified in a 
conventional clinical workup. 
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